Dr Carles Galceran on the Safety of Darolutamide with ADT and Docetaxel in Older Patients With mHSPC
Joan Carles Galceran, MD, PhD, discusses the safety of adding darolutamide to ADT and docetaxel in older patients with mHSPC.
Joan Carles Galceran, MD, PhD
Advertisement
Joan Carles Galceran, MD, PhD, is a medical oncologist in the Department of Oncology, Hospital Universitari Vall d'Hebron as Unit Coordinator genitourinary, central nervous system, sarcomas.
Articles by Joan Carles Galceran, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
5